Literature DB >> 27688100

Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences.

Danielle N Margalit1, Bhupendra Rawal2, Paul J Catalano2, Robert I Haddad3, Laura A Goguen4, Donald J Annino4, Sewanti A Limaye3, Jochen H Lorch3, Annie W Lavigne5, Jonathan D Schoenfeld5, David J Sher5, Roy B Tishler5.   

Abstract

PURPOSE: To describe patterns of failure (POF) after reirradiation (reRT) with intensity modulated radiation therapy (IMRT) for recurrent/second primary squamous cell carcinoma of the head and neck.
METHODS: From 08/2004-02/2013, 75 consecutive patients received reRT with IMRT. Gross tumor was generally treated with a 5mm planning target volume (PTV) margin. For postoperative cases, a 5mm PTV was added to the clinical target volume which included the postoperative bed. Elective neck coverage was not standard. POF were characterized by correlating the recurrent tumor location on CT-imaging with the reRT IMRT plan.
RESULTS: Patients received definitive reRT (55%) or postoperative reRT (45%) to a median 60Gy (range, 59.4-70Gy). Most patients (88%) received concurrent chemotherapy including induction (16%). The median overall survival was 1.8years. Isolated local-regional recurrence (LRR) was the most common failure-type (2-year cumulative incidence [CI] 22.5% [95% C.I. 13.6-32.7%]), but concurrent LRR and distant-failure occurred frequently (2-year CI LRR+distant-failure 19.6% [95% C.I. 11.3-29.5%]); isolated distant-failure was rare (2-year CI 5.7% [95% C.I. 1.8-12.8%]). The 2-year in-field control was 65% (95% C.I. 52-81%) reflecting encouraging control within the irradiated target. Patients with gross disease were more likely to recur in-field (p=0.02), whereas postoperative patients were more likely to recur out-of-field/marginally than in-field (p=0.02).
CONCLUSIONS: POF after reRT differ when treating gross disease or postoperatively and should be considered when delineating reRT targets. Aggressive local therapy resulted in favorable in-field control, yet there remains a high competing risk of regional and distant micrometastatic disease. Better systemic agents are needed to control clinically occult local-regional and distant disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Distant metastases; Head and neck cancer; Intensity modulated radiation therapy; Local regional recurrence; Oral cancer; Patterns of failure; Patterns of recurrence; Radiation therapy; Recurrent and metastatic; Recurrent head and neck cancer; Reirradiation; Squamous cell carcinoma; Surgical salvage

Mesh:

Year:  2016        PMID: 27688100     DOI: 10.1016/j.oraloncology.2016.07.012

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  3 in total

1.  Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy.

Authors:  Hideya Yamazaki; Yusuke Demizu; Tomoaki Okimoto; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka; Ryoongjin Oh
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

2.  Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.

Authors:  Jimmy J Caudell; Matthew C Ward; Nadeem Riaz; Sara J Zakem; Musaddiq J Awan; Neal E Dunlap; Derek Isrow; Comron Hassanzadeh; John A Vargo; Dwight E Heron; Samuel Marcrom; Drexell H Boggs; Chandana A Reddy; Joshua Dault; James A Bonner; Kristin A Higgins; Jonathan J Beitler; Shlomo A Koyfman; Mitchell Machtay; Min Yao; Andy M Trotti; Farzan Siddiqui; Nancy Y Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-12-01       Impact factor: 7.038

3.  A comparison of dose distributions in gross tumor volume between boron neutron capture therapy alone and combined boron neutron capture therapy plus intensity modulation radiation therapy for head and neck cancer.

Authors:  Jia-Cheng Lee; Keh-Shih Chuang; Yen-Wan Hsueh Liu; Tzung-Yi Lin; Yi-Chiao Teng; Ling-Wei Wang
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.